First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [21] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
    Baselga, Jose
    Campone, Mario
    Piccart, Martine
    Burris, Howard A., III
    Rugo, Hope S.
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    Gnant, Michael
    Pritchard, Kathleen I.
    Lebrun, Fabienne
    Beck, J. Thaddeus
    Ito, Yoshinori
    Yardley, Denise
    Deleu, Ines
    Perez, Alejandra
    Bachelot, Thomas
    Vittori, Luc
    Xu, Zhiying
    Mukhopadhyay, Pabak
    Lebwohl, David
    Hortobagyi, Gabriel N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06): : 520 - 529
  • [22] Fulvestrant: A guide to its use in hormone receptor-positive metastatic breast cancer in postmenopausal women in the EU
    Scott L.J.
    Croxtall J.D.
    McKeage K.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 42 - 47
  • [23] Fulvestrant A Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2011, 71 (03) : 363 - 380
  • [24] Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Clemons, Mark J.
    Cochrane, Brandy
    Pond, Gregory R.
    Califaretti, Nadia
    Chia, Stephen K. L.
    Dent, Rebecca Alexandra
    Song, Xinni
    Robidoux, Andre
    Parpia, Sameer
    Warr, David
    Rayson, Daniel
    Pritchard, Kathleen I.
    Levine, Mark N.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 153 - 162
  • [25] Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Mark J. Clemons
    Brandy Cochrane
    Gregory R. Pond
    Nadia Califaretti
    Stephen K. L. Chia
    Rebecca Alexandra Dent
    Xinni Song
    Andre Robidoux
    Sameer Parpia
    David Warr
    Daniel Rayson
    Kathleen I. Pritchard
    Mark N. Levine
    Breast Cancer Research and Treatment, 2014, 146 : 153 - 162
  • [26] A role for fulvestrant monotherapy in the first-line treatment of ER plus metastatic breast cancer?
    Mahtani, Reshma L.
    BREAST JOURNAL, 2020, 26 (02): : 109 - 111
  • [27] Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context
    Lee, Hye-Jae
    Lee, Tae-Jin
    Yang, Bong-Min
    Min, Junwon
    JOURNAL OF BREAST CANCER, 2010, 13 (03) : 286 - 298
  • [28] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Shimoi, Tatsunori
    Sagara, Yasuaki
    Hara, Fumikata
    Toyama, Tatsuya
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (03) : 340 - 346
  • [29] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [30] Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada
    Delea, T. E.
    Amdahl, J.
    Chit, A.
    Amonkar, M. M.
    CURRENT ONCOLOGY, 2013, 20 (05) : E371 - E387
12345